Left ventricular hypertrophy (LVH) can be elicited by several clinical conditions, including systemic hypertension, cardiac valve disease, and myocardial infarction, that increase cardiac workload. This adaptation is one facet of cardiac remodeling and subsequent heart failure (HF), which is a major cause of death in Western countries (1). In 1970, the Framingham Heart Study revealed that the presence of LVH alone is associated with increased mortality (1). Moreover, recent appraisals of this cohort have also linked LVH to arrhythmic sudden cardiac death (2). Interestingly, inhibition of LVH after transverse aortic constriction prevents HF and increases survival in genetically modified animals (3, 4).
noncoding RNAs that function mainly to regulate gene expression by hindering the translation of specific mRNAs at the posttranscriptional level (6) .
The biogenesis of miRs is a complex cascade. Briefly, from a transcript of the primary miR (pri-miR), approximately 60-to 70-nucleotide hairpin-structured precursor miR (pre-miR) is synthesized and exported to the cytoplasm, in which it is cleaved into the mature duplex miR (miR:miR*) by RNAse III. Subsequently, one of the two strands, the so-called passenger strand (also referred to as miR*), is released and degraded, whereas the other strand with the 5′ terminus that has less-stable base pairing is stripped away from the duplex and transferred to argonaute 2 (AGO) to become the guide strand or miR. While the guide strands target a miR-induced silencing complex (miRISC) to mRNAs with partially complementary sequences and silence them, the passenger strands are not generally considered to be of biological relevance (6) .
With respect to adaptive growth regulation, miRs have been identified and associated with several cardiovascular diseases, including neointimal proliferation after vascular injury (7, 8) , ischemic cardiomyo pathy (9) , and cardiac hypertrophy (10) (11) (12) (13) (14) . The importance of miRs in cardiovascular biology has also been demonstrated in animals with conditional deletion of the essential miRprocessing enzyme dicer1. Postnatal deletion of dicer1 in the myocardium results in spontaneous cardiac hypertrophy, interstitial fibrosis, and reactivation of fetal gene expression (15) . In addition, specific miRs have been identified in LVH and HF. For example, loss of miR-208a, which is encoded by the α-myosin heavy chain (Myh6) transcript, prevents pathological hypertrophic remodeling and fibrosis (11) . Cardiomyocyte-specific overexpression of the miR-212/132 family targets the antihypertrophic and proautophagic FOXO3 transcription factor and leads to pathological cardiac hypertrophy, HF, and death in mice, whereas animals lacking miR-212/132 are protected from pressure overload-induced HF (12) . Members of the miR-34 family of miRs are upregulated in mouse models of left ventricular pressure overload, and miR-23a controls hypertrophic growth of cardiomyocytes through signaling that involves calcineurin and NFAT.
Other miRs will likely be uncovered as regulators of hypertrophy, and some information is already available about circulating miRs that affect both hypertrophy and fibrosis. Among these circulating miRs are miR-29a and miR-30, which have been proposed as possible markers for use in LVH diagnosis (16) . Interestingly, miR-30 is downregulated upon angiotensin II administration, which promotes increased myocardial hypertrophy through excessive autophagy. In patients, miR-30 levels in the bloodstream are positively associated with left ventricular wall thickness. Intriguingly, miRs can be secreted from cells as vesicular bodies that arise from the plasma membrane or can be simply extruded by cells through membrane shedding (17) . Once miRs are packed into specific multivesicular bodies, they can undergo unidirectional transfer as part of cell-cell communication strategies, establishing an intercellular trafficking network that exchanges genetic information and elicits a variety of phenotypic changes (18) .
The role of exosomes in LVH
Exosomes are a specific subset of secreted membrane vesicles that are relatively homogeneous in size (30-100 nm) and differ from apoptotic bodies and microvesicles in their density and specific protein and nucleic acid composition. Multiple cells types secrete exosomes through fusion of multivesicular bodies with the plasma membrane. Recently, cell-to-cell exosome-dependent transfer of selected miRs from endothelial cells to vascular smooth muscle was reported within the vessel wall (19) . Moreover, a similar mechanism was described to mediate the transfer of AGO/miR complexes from platelets to endothelial cells (20) .
In this issue of the JCI, Bang and coworkers report a miR-containing exosomemediated intercellular communication system that operates within the myocardium. The data provided by Bang and colleagues support previous observations of miRcontaining exosomes mediating responses in other cell populations and confirm miRmediated intercellular communication in cardiac tissue (21) . In particular, Bang and colleagues revealed that miR-21*, a passenger strand micro RNA that is usually degraded inside the cytoplasm, is specifically packaged into and shuttled by exosomes from cardiac fibroblasts to cardiomyocytes, in which it promotes a hypertrophic response (Figure 1 and ref. 21) . Interestingly, Bang et al. demonstrated that fibroblast-derived exosomes are selectively enriched with miR-21* and exosome uptake by cardiomyocytes was dependent on temperature and actin. Once released within cardiomyocytes, exosome-derived miR-21* led to a substantial increase in cardiomyocyte cell size (Figure 1) .
Using proteomic profiling, Bang and colleagues identified sarcoplasmic protein sorbin and SH3 domain-containing protein 2 (SORBS2) and PDZ and LIM domain 5 (PDLIM5) as targets of miR-21* in cardiomyocytes, since both the encoding genes were strongly silenced in miR-21*-transfected cardiomyocytes. Of note, in the same cardiomyocyte model, knock down of SORBS2 and PDLIM5 resulted in marked cellular hypertrophy. SORBS2 localizes to Z-disks, in which it influences the contractile and elastic properties of cardiac sarcomeres (22) . Interestingly, release of SORBS2 from damaged cardiac tissue into the bloodstream upon fatal acute myocardial infarction has been described recently (23) . PDLIM5 is highly conserved across species and, like SORBS2, colocalizes at Z-disks and is directly associated with dilated cardiomyopathy (24) and indirectly involved in human hypertrophic cardiomyopathy (25) . Collectively, these findings raise the question of whether miR-21* plays a role in the development of HF in Z-disk disruption models.
The study by Bang and colleagues has also provided new insights for LVH. In fact, miR-21* was detected in pericardial fluid of mice with transverse aortic constriction-induced cardiac hypertrophy (21) , thus confirming in vivo that miR-21* plays an important role in regulation of the cardiac fibroblast secretome and in determining a hypertrophic response (Figure 1 ). In addition, Bang and associates were able to demonstrate that systemic injection of 80 mg/kg of a miR-21* antagomir at day 0 and day 2 prevented LVH induction by angiotensin II administration.
Future implications
The most intriguing aspect of the study performed by Bang and coworkers is the identification of a unique mechanism in which cardiac fibroblasts influence the hypertrophic response of cardiomyocytes (21) . If confirmed by further studies, these findings provide a potential therapeutic target to interfere with cardiovascular diseases at a physiopathological level. Although fibroblast-derived miR-21* promotes an undesirable pathologic hypertrophy of cardiomyocytes, the identification of the exosome-dependent miR secretion mechanism has been addressed extensively. These vesicles and their miR cargo will likely represent an exciting therapeutic venue in the years to come for cardiovascular biology.
Many questions that pertain to the selective delivery of vesicle content to target cells, exosomes clearance in biologic fluids, and the possibility of a ligand-receptor interaction of surface membranes remain to be answered. The next steps in this field of research will be to further evaluate how miR-containing vesicles promote disease. Moreover, adjunctive efforts are needed to investigate miR-21* inhibition under pressure overload conditions on left ventricular function and survival. Finally, while the clinical use of antagomirs for human
Figure 1
Dynamics of fibroblast-mediated exosome secretion and pivotal miRs involved in cardiac hypertrophy. Following cardiac stress, fibroblasts secrete miR-enriched exosomes, which are enriched with miR-21*. Cardiomyocytes take up the fibroblast-secreted exosomes, which release miR-21*. Targeted knockdown of SORBS2 and PDLIM5 by miR-21* promotes hypertrophy. Many miRs that regulate hypertrophy have been identified and can be considered as tissue specific, circulating, and secreted. Among the latter, only miR-21* has been detected in pericardial fluid in the context of cardiac hypertrophy (21) . therapeutics looks to be part of future strategies for treating a variety of diseases (for example, miravirsen, a miR-122 antagomir, is currently being evaluated in a phase IIb trial for the treatment of virus Crelated hepatitis; ref. 26) , it remains unclear whether exosomes/microparticles can be exploited for selectively targeting and delivering biological therapies based on the modulation of miR effects.
